Liquidityhelp
lock$28.32K
Total value locked
$1.78K
24h volume
Yieldhelp
trending_up2.3%
advertised APRFee yield, annualized
≈ -30.5%
adjusted · net of IL (est.)
My Position
account_balance_walletAI Verdict
Proceed with Caution
WealthVille AI evaluation verdict for this liquidity pool investment opportunity.
Enter only with a defined price range and set an exit trigger for a material TVL drain or a sustained loss of fee activity; without a current range-occupancy reading, monitor the position manually rather than assuming the initial range remains productive.
syncAI analysis is refreshing in the background
Performance Breakdown
| Metric | 24h / Day | 7d / Week | 30d / Month |
|---|---|---|---|
| Total APR | 2.3% | — | — |
| Fee APR | 2.3% | — | — |
| Volume | $1.78K | — | — |
| Fees Earned | $4.45 | — | — |
Data sourced from Raydium Protocol, Birdeye, and DexScreener. Updated every snapshot cycle.
Efficiency Metrics
ComputedDeterministic efficiency metrics computed from on-chain data for this liquidity pool. All values are calculated directly from pool analytics — not AI-generated.
Pool Rankings
#1 of 2 BIO-DRUGS pools
by AI Farmer Score
#5509 of 91854 on raydium-amm
by AI Farmer Score
Top 8% of all Solana pools
overall rank #10414 of 148664
How This Pool Works
Beginner FriendlyThis page provides real-time AI analytics and performance data for the BIO-DRUGS liquidity pool on Raydium AMM. Data is sourced from on-chain Solana activity, Birdeye, DexScreener, and CoinGecko.
Providing liquidity here means depositing BIO and DRUGS into a shared trading pool so other users can swap between them. You receive part of the trading fees, but your token mix can change and may be worth less than simply holding both tokens if their prices move sharply.
Pool Analysis
trending_upYield Source Breakdown
Yield decomposes into 2.3% from trading fees and 0.0% from rewards. 99% means the displayed return is funded by swaps rather than token emissions. No dependable reward schedule is established for this pool, so emission decay and reward duration should not be treated as sources of additional return; the relevant exit consideration is whether fee volume continues to support 2.3%.
shieldRisk Assessment
A current seven-day impermanent-loss reading is not available, and recent tick occupancy is also not reported, so realized price divergence and range utilization cannot be quantified from these metrics. As a MEMECOIN pool, BIO-DRUGS is exposed to abrupt repricing, shallow liquidity, and correlation breakdown between the two tokens. Emission decay appears less central because the displayed reward component is 0.0%, but exit timing still matters if trading activity weakens or either token loses liquidity.
tollBIO Context
BIO is one side of the BIO-DRUGS trading pair and gives the LP exposure to BIO's price relative to DRUGS. Its liquidity depth outside this pool is not established here, so a sharp BIO move may be difficult to hedge or exit without additional slippage. If BIO appreciates or falls materially relative to DRUGS, the LP's inventory shifts toward the weaker asset and can create divergence loss.
tollDRUGS Context
DRUGS is the other side of the pair, with the same relative-price and execution considerations as BIO. Its broader liquidity depth is not established here, so a DRUGS selloff can make the pool's remaining inventory more concentrated in DRUGS. Relative DRUGS price moves also determine the LP's divergence exposure even when fee income continues.
lightbulbSimple Explanation
Providing liquidity here means depositing BIO and DRUGS into a shared trading pool so other users can swap between them. You receive part of the trading fees, but your token mix can change and may be worth less than simply holding both tokens if their prices move sharply.
Token Details
Pool Details
- Pool Address
- G7k3VPqq9e1wPQ89x2fJnmAtTsndQi24VjKtoLhpm8WQ
- Protocol
- Raydium AMM
- Chain
- solana
- Fee Tier
- —
- Pool Type
- AMM
- Token A
- BIO (bioJ9JTq…)
- Token B
- DRUGS (3937Rsye…)
- Created
- 9/14/2026
Explore More
Similar Pools — Same Protocol
APR
13%
APR
0%
APR
0%
APR
6%
By Protocol
hubAll raydium-amm poolsarrow_forwardBlockchain
dnsAll Solana poolsarrow_forwardNon-Custodial
Your funds are never held by WealthVille. All positions are on-chain.
Verified Data Sources
Raydium, Birdeye, DexScreener, CoinGecko, LlamaYield
AI-Powered Analysis
Proprietary scoring model trained on historical Solana DeFi data
⚠️ WealthVille AI analytics are for informational purposes only. APR, TVL, and AI scores are based on historical and real-time data and do not constitute financial advice. DeFi investments carry significant risk including impermanent loss and smart contract risk. Always do your own research.
Frequently Asked Questions
The displayed reward component is 0.0%, while fee income is 2.3% and fee sustainability is 99%. Because no dependable reward schedule is established, emission decay is not a quantified source of current APR; future incentives should be treated as uncertain rather than assumed.
The displayed reward component is 0.0%, while fee income is 2.3% and fee sustainability is 99%. Because no dependable reward schedule is established, emission decay is not a quantified source of current APR; future incentives should be treated as uncertain rather than assumed.
The reward component would provide no support beyond 0.0%, leaving trading fees of 2.3% as the stated yield source. If swap activity does not increase, the position would then depend entirely on fee generation and the changing BIO-to-DRUGS price relationship.
The reward component would provide no support beyond 0.0%, leaving trading fees of 2.3% as the stated yield source. If swap activity does not increase, the position would then depend entirely on fee generation and the changing BIO-to-DRUGS price relationship.
Risk is elevated by memecoin price gaps, uncertain external liquidity, and the possibility that one token becomes difficult to sell. The pool also has a 0.06x volume-to-TVL ratio, so fee generation may not compensate for a large relative move between BIO and DRUGS.
Risk is elevated by memecoin price gaps, uncertain external liquidity, and the possibility that one token becomes difficult to sell. The pool also has a 0.06x volume-to-TVL ratio, so fee generation may not compensate for a large relative move between BIO and DRUGS.
Use a predefined trigger based on a material TVL drain, weakening fee activity, or a price move that leaves the chosen range. For BIO-DRUGS, reassess promptly when liquidity or executable volume deteriorates because exit timing can matter more than the stated 2.3%.
Use a predefined trigger based on a material TVL drain, weakening fee activity, or a price move that leaves the chosen range. For BIO-DRUGS, reassess promptly when liquidity or executable volume deteriorates because exit timing can matter more than the stated 2.3%.
It cannot be estimated reliably because recent impermanent-loss history is not available and future fee volume is uncertain. Break-even depends on whether accumulated 2.3% offsets the position's divergence loss after accounting for changes in BIO and DRUGS prices.
It cannot be estimated reliably because recent impermanent-loss history is not available and future fee volume is uncertain. Break-even depends on whether accumulated 2.3% offsets the position's divergence loss after accounting for changes in BIO and DRUGS prices.
